• woman_running

    Patients deserve better tools for controlling their ulcerative colitis

    Learn More
  • goblet_cells

    Zoenasa is the first mesalamine combination therapy designed for improved efficacy in ulcerative colitis

    Read Now
  • healthy_colon

    Altheus recently completed enrollment of a Phase 2 clinical study for Zoenasa in ulcerative colitis

    Learn More

Phase 2 Study Recently Completed

Altheus has completed enrolling patients in ZA201, a clinical study of Zoenasa in patients with left-sided ulcerative colitis. Topline data will be available in Spring 2014.

Read more →


Advancing Front-Line Therapy in UC

Zoenasa is a fixed-dose combination of mesalamine plus a second potent anti-inflammatory. In preclinical and early clinical studies, Zoenasa showed a 50-100% improvement over mesalamine alone.

Learn More →